Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR5A2 | O00482 | 1/20 | 0.54 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.54 |
| ▸ | GLRA3 | O75311 | 1/20 | 0.53 |
| ▸ | GLRB | P48167 | 1/20 | 0.53 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.46 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | RXRB | P28702 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL123001 | 1.00 | NR5A2 (0.54) | NR5A2NR5A1GLRA3GLRBAKR1C2 | |
| SCHEMBL132940 | 0.98 | NR5A2 (0.55) | NR5A2NR5A1GLRA3GLRBAKR1C2 | |
| SCHEMBL3854450 | 0.96 | NR5A2 (0.54) | NR5A2NR5A1GLRA3GLRBAKR1C2 | |
| SCHEMBL12477477 | 0.96 | NR5A2 (0.54) | NR5A2NR5A1GLRA3GLRBAKR1C2 | |
| SCHEMBL12477039 | 0.96 | NR5A2 (0.54) | NR5A2NR5A1GLRA3GLRBAKR1C2 | |
| SCHEMBL3445413 | 0.96 | NR5A2 (0.54) | NR5A2NR5A1GLRA3GLRBAKR1C2 | |
| SCHEMBL12477342 | 0.96 | NR5A2 (0.54) | NR5A2NR5A1GLRA3GLRBAKR1C2 | |
| SCHEMBL8674609 | 0.96 | NR5A2 (0.54) | NR5A2NR5A1GLRA3GLRBAKR1C2 | |
| SCHEMBL11224399 | 0.96 | NR5A2 (0.54) | NR5A2NR5A1GLRA3GLRBAKR1C2 | |
| SCHEMBL15261147 | 0.96 | NR5A2 (0.54) | NR5A2NR5A1GLRA3GLRBAKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 688 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2658895-B1 | ALKYLENE OXIDE POLYMERIZATION USING A DOUBLE METAL CYANIDE CATALYST COMPLEX AND A MAGNESIUM, GROUP 3-GROUP 15 METAL OR LANTHANIDE SERIES METAL COMPOUND | DOW GLOBAL TECHNOLOGIES LLC (US) | 2021-06-23 | — | — | EP | claimed |
| US-9040657-B2 | Alkylene oxide polymerization using a double metal cyanide catalyst complex and a magnesium, Group 3-Group 15 metal or lanthanide series metal compound | DOW GLOBAL TECHNOLOGIES LLC (US) | 2015-05-26 | — | — | US | claimed |
| CN-1155857-C | Toner for developing electrostatic images and process for production thereof | 佳能株式会社 | 2004-06-30 | — | — | CN | claimed |
| CN-1197939-A | Toner for developing electrostatic images and process for production thereof | CANON KK (JP) | 1998-11-04 | — | — | CN | claimed |
| US-5759729-A | A DRY TONER COMPRISING A RESIN, PHOTOCHROMATIC SPIROPYRAN, -OXAZINE OR -THIOPYRAN DYE AND A CHARGE CONTROL AGENT;ELECTROGRAPHY; XEROGRAPHY | XEROX CORPORATION (US) | 1998-06-02 | — | — | US | claimed |
| US-5281502-A | Tri-level imaging processes with adjustable color | XEROX CORPORATION (US) | 1994-01-25 | — | — | US | claimed |
| EP-0531146-A1 | Improved toner and process for forming two-color images | XEROX CORPORATION (US) | 1993-03-10 | — | — | EP | claimed |
| EP-4086705-B1 | TONER | CANON KK (JP) | 2026-03-25 | — | — | EP | disclosed |
| EP-4036657-B1 | MAGNETIC CARRIER, TWO-COMPONENT DEVELOPER, AND REPLENISHMENT DEVELOPER | CANON KK (JP) | 2026-03-11 | — | — | EP | disclosed |
| EP-3893059-B1 | WHITE TONER | CANON KK (JP) | 2026-02-18 | — | — | EP | disclosed |
| US-12547089-B2 | Toner and toner production method | CANON KABUSHIKI KAISHA (JP) | 2026-02-10 | — | — | US | disclosed |
| US-12487539-B2 | Fine particle, external additive for toners, and toner | CANON KABUSHIKI KAISHA (JP) | 2025-12-02 | — | — | US | disclosed |
| US-20250334892-A1 | FINE POWDER FOR TONER AND TONER | CANON KK (JP) | 2025-10-30 | — | — | US | disclosed |
| US-5451466-A | Electrophotographic use, reduced heat and energy required for toner fusion, styrene copolymer, indan or derivative | XEROX CORPORATION (US) | 1995-09-19 | — | — | US | disclosed |
| US-5451458-A | Electrography | XEROX CORPORATION (US) | 1995-09-19 | — | — | US | disclosed |
| US-5439770-A | Blend of a binder resin and an iron complex charge control agent | CANON KABUSHIKI KAISHA (JP) | 1995-08-08 | — | — | US | disclosed |
| EP-0621513-A2 | Toner for developing electrostatic image, image forming apparatus and process cartridge | CANON KABUSHIKI KAISHA (JP) | 1994-10-26 | — | — | EP | disclosed |
| US-5281502-A | Tri-level imaging processes with adjustable color | XEROX CORPORATION (US) | 1994-01-25 | — | — | US | disclosed |
| EP-0531146-A1 | Improved toner and process for forming two-color images | XEROX CORPORATION (US) | 1993-03-10 | — | — | EP | disclosed |
| EP-0531146-A1 | Improved toner and process for forming two-color images | XEROX CORPORATION (US) | 1993-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12547089-B2 | Toner and toner production method | SMC4, EZR, SMC2 | NR5A2 2620/4885NR5A1 3965/4885GLRA3 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.